ClinicalTrials.Veeva

Menu

CD34 Selection of the Peripheral Blood Stem Cell Graft for Autologous Transplant

Stanford University logo

Stanford University

Status and phase

Completed
Phase 2
Phase 1

Conditions

Breast Cancer

Treatments

Procedure: high dose chemo then auto hematopoietic cell transplant

Study type

Interventional

Funder types

Other

Identifiers

NCT00186680
NCT00186680
BMT86

Details and patient eligibility

About

Evaluate the feasibility and safety of autologous transplantation of CD34+Thy-1+ hematopoietic stem cells afer high dose marrow ablative chemotherapy in patients with breast cancer.

Full description

Selection of CD34+THY-1 Positive Cells From Peripheral Blood Cells Procured for Autologous Hematopoietic Support Following High Dose Treatment with BCNU, Cyclophosphamide & Cisplatin for Stage IV Breast Cancer & Limited Prior Treatment

Enrollment

99 estimated patients

Sex

All

Ages

19 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:- stage IV breast cancer

  • primary breast cancer does not express CD34+
  • adequate organ function
  • no evidence of active infection Exclusion Criteria:- chemotherapy within 4 weeks
  • CNS disease

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems